The last one month has been better as the stock has recovered from the correction. It is up 10% over last one month. It is up 78% on a ytd basis, and has done well even over the longer term. Fundamentals have improved over time, though the last earnings were not as per expectations. Viewed in isolation they were not bad at all. The revival in the stock has again taken the valuations a bit higher. Now the P/E (ttm) is around 21.5 and the forward P/E is 16.6. Price to sales is 4.22 and price to book ratio is 2.3. The ttm profit margin is around 20%, with revenues around $217 million and net income of $43 million. The balance sheet is strong as the company has $259 million cash and zero debt. Earnings for the third quarter will be crucial in determining the short term trend for the stock. It is important that the estimates are exceeded so that the uptrend can gain strength. The earnings are about a month away. There has been some selling by insiders recently though that could be attributed to different reasons. There have been articles recommending to buy the stock based on the future prospects. The unique business model of RPXC has been highlighted as a reason for being positive about the stock. The market is growing and the potential is huge. Spherix (SPEX), which had recently acquired several patents, has filed claims against big companies. The SA article last month stated that RPXC is undervalued because the entire company can be bought for less than the cost of its patent portfolio. Recently, there has been an increasing desire amongst companies to pursue different strategies for monetizing the value of their patents. Many prefer to avoid the costly and time consuming litigation route. RPXC has the expertise to leverage the growth in demand to its advantage.